<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437202</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-H-64</org_study_id>
    <nct_id>NCT01437202</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia</brief_title>
  <acronym>VATIC</acronym>
  <official_title>Retrospective Study to Validate Pharmacogenetics Model for Imatinib Metabolism in Patients With Chronic Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, retrospective, observational study to validate a pharmacogenetics
      model for imatinib metabolism and resistance in patients with chronic myeloid leukemia among
      patients in different independent cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The activity of Imatinib(IM) is mediated by blocking the activity of BCR/ABL tyrosine
           kinase in CML cells. However, some of the patients failed to achieve optimal response,
           and a substantial proportion of patients develop resistance to IM.

        2. IM is a substrate for the adenosine triphosphate binding cassette (ABC) transporters,
           ABCB1 and ABCG2, while the active uptake of IM into cells is mediated by the human
           organic cationic transporter-1 (hOCT1). Also, IM is metabolized through first pass drug
           metabolism by the cytochrome P450 - CYP3A4 and CYP3A5. In addition, it is delivered in a
           bound form with a plasma protein referred to Î±1-acid glycoprotein (AGP).

        3. Accordingly, the intracellular or systemic level of imatinib should be influenced by
           these factors such as ABCB1, ABCG2, hOCT1, CYP3A4, CYP3A5 or AGP genes. Inter-individual
           variability of 5 candidate genes associated with drug transport/metabolism (i.e. ABCB1,
           ABCG2, hOCT1, CYP3A4/3A5 and AGP) could affect the expression of corresponding proteins,
           thus influencing the treatment outcomes of imatinib therapy.

        4. In the investigators' previous study, the investigators reported the cumulative
           incidences of MCyR and CCyR was significantly affected by the predictive model using 2
           genotypes and disease stage. These predictive models for CCyR/MMoR or LOR/treatment
           failure seemed to work well. However, external validation of these predictive models is
           warranted especially using ethnically different independent cohort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Median time to CCyR (complete cytogenetic response)</measure>
    <description>Difference of median time to CCyR between cohorts according to the risk stratification by gene analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variance of Genotypes from CML patients with Korean ethnicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to MCyR (Major cytogenetic responses)</measure>
    <description>Difference of median time to MCyR between cohorts according to the risk stratification by gene analysis</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</condition>
  <arm_group>
    <arm_group_label>high risk group</arm_group_label>
    <description>Identified by the predictive model using 2 genotypes and disease stage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intermediate risk group</arm_group_label>
    <description>Identified by the predictive model using 2 genotypes and disease stage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low risk group</arm_group_label>
    <description>Identified by the predictive model using 2 genotypes and disease stage</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood 4cc
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were diagnosed as chronic myeloid leukemia, treated with imatinib more than 3
        months, at Asan Medical Center, Seoul, Korea.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic myeloid leukemia of any stage including chronic phase, accelerated or blastic
             phase.

          -  Age&gt;18 years

          -  Complete set of clinical data available for review (demographic data, stage, treatment
             history, cytogenetic reports, and latest BCR/ABL RQ-PCR results)

          -  Treated with imatinib mesylate at least 3 months

        Exclusion Criteria:

          -  Treated with imatinib mesylate less than 3 months

          -  Not agree with the intention of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Won Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center, Sungjyunkwan University School of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae-Young Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital, University of Toronto</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 1;104(7):1979-88. Epub 2004 Jun 15.</citation>
    <PMID>15198956</PMID>
  </reference>
  <reference>
    <citation>Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006 Dec 19;145(12):913-23. Review.</citation>
    <PMID>17179059</PMID>
  </reference>
  <reference>
    <citation>Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001 Aug 3;293(5531):876-80. Epub 2001 Jun 21.</citation>
    <PMID>11423618</PMID>
  </reference>
  <reference>
    <citation>Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003 Mar 15;101(6):2368-73.</citation>
    <PMID>12609962</PMID>
  </reference>
  <reference>
    <citation>Awidi A, Salem II, Najib N, Mefleh R, Tarawneh B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison. Leuk Res. 2010 Jun;34(6):714-7. doi: 10.1016/j.leukres.2009.08.005. Epub 2009 Sep 9.</citation>
    <PMID>19744707</PMID>
  </reference>
  <reference>
    <citation>Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther. 2006 Aug;80(2):192-201.</citation>
    <PMID>16890580</PMID>
  </reference>
  <results_reference>
    <citation>Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009 Jul 15;15(14):4750-8. doi: 10.1158/1078-0432.CCR-09-0145. Epub 2009 Jul 7.</citation>
    <PMID>19584153</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Dae-Young Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>imatinib</keyword>
  <keyword>drug resistance</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

